Targeted therapy of atherosclerosis by zeolitic imidazolate framework-8 nanoparticles loaded with losartan potassium <i>via</i> simultaneous lipid-scavenging and anti-inflammation

Sheng, Jie; Zu, Zi Yue; Zhang, Yugang; Zhu, Haitao; Qi, Jianchen; Zheng, Tao; Tian, Ying; Zhang, Long Jiang

doi:10.1039/d2tb00686c

Cited by 10 publications

(5 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 207 Sheng et al developed zeolitic imidazolate framework-8 (ZIF-8) NPs loaded with losartan potassium LP (LP@ZIF-8) for plaque-targeting using the EPR-like effect. 208 ZIF-8 is a material that could facilitate autophagic activity in foam cells, stimulate RCT, and regulate lipid activity. ZIF-8 could disassemble due to the weak acid microenvironment (pH 5.5) in diseased aortic tissue releasing the encapsulated LP and downregulating ROS and the inflammatory factors (IL-1β, IL-6, TNFα).…”

Section: Atherosclerosis (As)mentioning

confidence: 99%

Multifunctional nanoparticle-mediated combining therapy for human diseases

Li,

Peng,

Zoulikha

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Combining existing drug therapy is essential in developing new therapeutic agents in disease prevention and treatment. In preclinical investigations, combined effect of certain known drugs has been well established in treating extensive human diseases. Attributed to synergistic effects by targeting various disease pathways and advantages, such as reduced administration dose, decreased toxicity, and alleviated drug resistance, combinatorial treatment is now being pursued by delivering therapeutic agents to combat major clinical illnesses, such as cancer, atherosclerosis, pulmonary hypertension, myocarditis, rheumatoid arthritis, inflammatory bowel disease, metabolic disorders and neurodegenerative diseases. Combinatorial therapy involves combining or co-delivering two or more drugs for treating a specific disease. Nanoparticle (NP)-mediated drug delivery systems, i.e., liposomal NPs, polymeric NPs and nanocrystals, are of great interest in combinatorial therapy for a wide range of disorders due to targeted drug delivery, extended drug release, and higher drug stability to avoid rapid clearance at infected areas. This review summarizes various targets of diseases, preclinical or clinically approved drug combinations and the development of multifunctional NPs for combining therapy and emphasizes combinatorial therapeutic strategies based on drug delivery for treating severe clinical diseases. Ultimately, we discuss the challenging of developing NP-codelivery and translation and provide potential approaches to address the limitations. This review offers a comprehensive overview for recent cutting-edge and challenging in developing NP-mediated combination therapy for human diseases.

show abstract

Section: Atherosclerosis (As)mentioning

confidence: 99%

Multifunctional nanoparticle-mediated combining therapy for human diseases

Li,

Peng,

Zoulikha

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…utilized losartan potassium (LP) loaded in ZIF‐8 (LP@ZIF‐8) to achieve simultaneous anti‐inflammation and lipid scavenging strategy in AS treatment. [ 159 ] Due to the enhanced permeability and retention (EPR) effect, LP@ZIF‐8 was able to accumulate within AS tissues. In the acidic lysosome of macrophages, LP@ZIF‐8 was disintegrated to release anti‐inflammatory LP.…”

Section: Mofs‐based Therapeutic Agentsmentioning

confidence: 99%

“…[146] Copyright 2020, American Association for the Advancement of Science. RGD-PMCS Thrombosis [153] uPA@CFs Thrombosis [154] LP@ZIF-8 Atherosclerosis [159] RUFI Atherosclerosis [160] AM@ZIF@NM Atherosclerosis [161] Hep-(Rap@MOF)@PCL Atherosclerosis [166] MOF-Fe/Ag Atherosclerosis [167] PCL/Cu-MOF Atherosclerosis [168] EM-Z90 Critical limb ischemia [176] HPC@ZIF@DATS Critical limb ischemia [177] HA-CAG@ZIF8@CO Critical limb ischemia [178] UIO-66-NH 2 @GYY4137@BMP6 Critical limb ischemia [179] Ca-MOF@miR-124 Ischemic stroke [180] DNIC@MOF Hypertension [183]…”

Section: Mofs-based Therapeutic Agentsmentioning

confidence: 99%

See 1 more Smart Citation

Bioactive Metal–Organic Frameworks as a Distinctive Platform to Diagnosis and Treat Vascular Diseases

Liu,

Li,

Wang

et al. 2024

Small

View full text Add to dashboard Cite

Vascular diseases (VDs) pose the leading threat worldwide due to high morbidity and mortality. The detection of VDs is commonly dependent on individual signs, which limits the accuracy and timeliness of therapies, especially for asymptomatic patients in clinical management. Therefore, more effective early diagnosis and lesion‐targeted treatments remain a pressing clinical need. Metal–organic frameworks (MOFs) are porous crystalline materials formed by the coordination of inorganic metal ions and organic ligands. Due to their unique high specific surface area, structural flexibility, and functional versatility, MOFs are recognized as highly promising candidates for diagnostic and therapeutic applications in the field of VDs. In this review, the potential of MOFs to act as biosensors, contrast agents, artificial nanozymes, and multifunctional therapeutic agents in the diagnosis and treatment of VDs from the clinical perspective, highlighting the integration between clinical methods with MOFs is generalized. At the same time, multidisciplinary cooperation from chemistry, physics, biology, and medicine to promote the substantial commercial transformation of MOFs in tackling VDs is called for.

show abstract

“…Sheng et al used ZIF-8 as a vehicle to establish a nano losartan potassium (LP)-loaded ZIF-8 drug delivery system. As a zinc-based metal organic skeleton, nanoscale ZIF-8 achieved sustained and stable release of Zn 2+ in vivo , which synergistically relieved chronic inflammation and regulated lipid metabolism with LP [ 131 ].…”

Section: Engineering Strategies For Metallic Ion Delivery For Cardiov...mentioning

confidence: 99%

Exogeneous metal ions as therapeutic agents in cardiovascular disease and their delivery strategies

Hong,

Tian,

Zhu

et al. 2023

Regenerative Biomaterials

View full text Add to dashboard Cite

Metal ions participate in many metabolic processes in the human body, and their homeostasis is crucial for life. In cardiovascular diseases (CVDs), the equilibriums of metal ions are frequently interrupted, which are related with a variety of disturbances of physiological processes leading to abnormal cardiac functions. Exogenous supplement of metal ions has the potential to work as therapeutic strategies for the treatment of CVDs. Compared with other therapeutic drugs, metal ions possess broad availability, good stability and safety, and diverse drug delivery strategies. The delivery strategies of metal ions are important to exert their therapeutic effects and reduce the potential toxic side effects for cardiovascular applications, which are also receiving increasing attentions. Controllable local delivery strategies for metal ions based on various biomaterials are constantly being designed. In this review, we comprehensively summarized the positive roles of metal ions in the treatment of CVDs from three aspects: protecting cells from oxidative stress, inducing angiogenesis, and adjusting the functions of ion-channels. In addition, we introduced the transferability of metal ions in vascular reconstruction and cardiac tissue repair, as well as the currently available engineered strategies for the precise delivery of metal ions, such as integrated with nanoparticles, hydrogels, and scaffolds.

show abstract

Targeted therapy of atherosclerosis by zeolitic imidazolate framework-8 nanoparticles loaded with losartan potassium via simultaneous lipid-scavenging and anti-inflammation

Abstract: Atherosclerosis (AS) is a condition associated with dysfunctional lipid metabolism and an inflammatory immune microenvironment that remains the leading cause of severe cardiovascular events. Drugs exhibiting both anti-inflammatory and lipid-scavenging...

Cited by 10 publications

References 58 publications

Multifunctional nanoparticle-mediated combining therapy for human diseases

Multifunctional nanoparticle-mediated combining therapy for human diseases

Bioactive Metal–Organic Frameworks as a Distinctive Platform to Diagnosis and Treat Vascular Diseases

Exogeneous metal ions as therapeutic agents in cardiovascular disease and their delivery strategies

Contact Info

Product

Resources

About